Ibragimova Regina

Ibragimova Regina

Biography

She graduated Bashkir State University with a degree in Chemistry chemical technology, received an additional education degree in the Sechenov University advanced training program for specialists responsible for production, quality and. labeling of medicinal products pharmaceutical industries She began her career as a technologist at the company, four Pharmstandard years later, as a leading process engineer, she participated in the launch of a pharmaceutical plant in. After Kazan the completion of the project, she was appointed chief technologist.

2025: Director of Petrovax Farm Production Complex

Russian biotechnological company Petrovax Farm on March 5, 2025 on changes in the composition of top management. Regina Ibragimova became the director of the production complex in Podolsk. Its purpose is an important step in the development of the company and the implementation of biotechnology projects.

Regina Ibragimova joined the Petrovax Farm team in 2021 as chief technologist, in 2024 she was appointed production director, and from 2025 - plant director. In this role, it faces important strategic tasks: expanding the production of the full cycle, including the production of substances, increasing the production of demanded vaccines and biotechnological drugs.

Among the key areas is the localization of the complete cycle of the immuno-oncological drug Areima (camrelizumab) for the treatment of nasopharyngeal and esophageal cancer, which was registered in Russia in 2024. Another significant project - the production of the orphan drug Fabagal for the therapy of rare genetic disease Fabri - in 2024, the company completed the complete transfer of the technology for the production of the drug, including biosynthesis of the substance, in cooperation with the N.F. Gamaleya.

The launch and localization of Fabagal has become one of the most significant achievements of our team, "said Regina Ibragimova, director of the Petrovax Farm plant. - This is a powerful, ambitious biotechnology project that we managed to implement in a fairly short time and which we are really proud of. Bringing drugs to the market will require expanding production, increasing capacity, and automating business processes. The construction of a biotechnological complex for the production of substances and genetically engineered drugs, which the company plans to supply not only to the Russian market, but also for export, is nearing completion.

In a similar position at Petrovax Farm, in just three years, Regina Ibragimova significantly changed the team structure and optimized technological processes. As of March 2025, she heads the Petrovax production complex in the Moscow Region, which includes four production lines, biochemical, control and analytical, microbiological laboratories, engineering systems and a pharmaceutical warehouse.